FGF-2 variants having N-terminal deletions and increased receptor selectivity and methods of use thereof
US9862753B2 · kind B2 · utility
0Cited by
26References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 23, 2015 |
| Grant date | Jan 9, 2018 |
| Priority date | — |
| Expiry date | Feb 23, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.